Proteostasis Therapeutics Inc  

(Public, NASDAQ:PTI)   Watch this stock  
Find more results for TSE:PTI
12.36
-2.91 (-19.06%)
After Hours: 12.15 -0.21 (-1.70%)
Jun 27, 7:52PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.09 - 15.27
52 week 5.27 - 20.19
Open 15.27
Vol / Avg. 159,421.00/75,491.00
Mkt cap 214.76M
P/E     -
Div/yield     -
EPS -1.68
Shares 19.14M
Beta     -
Inst. own 48%
Mar 30, 2016
Proteostasis Therapeutics Inc to Hold Investor Conference Call and Webcast to Outline Scientific and Corporate Updates
Mar 30, 2016
Proteostasis Therapeutics Inc to Hold Investor Conference Call and Webcast to Outline Scientific and Corporate Updates
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -690.07% -580.71%
Operating margin -692.49% -568.97%
EBITD margin - -562.66%
Return on average assets -91.06% -164.35%
Return on average equity - -
Employees 42 -
CDP Score - -

Address

200 Technology Sq Fl 4
CAMBRIDGE, MA 02139-3578
United States - Map
+1-617-2250096 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.

Officers and directors

Christopher K. Mirabelli Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Meenu Chhabra President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Lance E. Thibault Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Age: 49
Bio & Compensation  - Reuters
Po-Shun Lee M.D. Executive Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
Janet L. Smart Vice President - Intellectual Property & Legal Affaris
Bio & Compensation  - Reuters